PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15670575-0 2005 Transient up-regulation of P-glycoprotein reduces tacrolimus absorption after ischemia-reperfusion injury in rat ileum. Tacrolimus 50-60 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 27-41 16457995-1 2006 The significance of intestinal P-glycoprotein (P-gp) in determining the oral bioavailability of tacrolimus has been still controversial. Tacrolimus 96-106 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 31-45 16457995-1 2006 The significance of intestinal P-glycoprotein (P-gp) in determining the oral bioavailability of tacrolimus has been still controversial. Tacrolimus 96-106 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 47-51 16457995-2 2006 In this study, we reevaluated the interaction of tacrolimus with P-gp in the rat small intestine, by evaluating its absorption from the rat small intestine and its modulating effect on the absorption of known P-gp substrates (digoxin, methylprednisolone, and vinblastine). Tacrolimus 49-59 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 65-69 16457995-2 2006 In this study, we reevaluated the interaction of tacrolimus with P-gp in the rat small intestine, by evaluating its absorption from the rat small intestine and its modulating effect on the absorption of known P-gp substrates (digoxin, methylprednisolone, and vinblastine). Tacrolimus 49-59 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 209-213 21615281-3 2011 In order to inhibit the efflux of P-glycoprotein (P-gp) for tacrolimus, which is the substrate of P-gp, the excipients which show the inhibition effect to P-gp, such as tocopheryl polyethylene glycol succinate (TPGS) and Cremophor EL40, were chosen in the SMEDDS formulations. Tacrolimus 60-70 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 34-48 21615281-3 2011 In order to inhibit the efflux of P-glycoprotein (P-gp) for tacrolimus, which is the substrate of P-gp, the excipients which show the inhibition effect to P-gp, such as tocopheryl polyethylene glycol succinate (TPGS) and Cremophor EL40, were chosen in the SMEDDS formulations. Tacrolimus 60-70 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 50-54 21615281-3 2011 In order to inhibit the efflux of P-glycoprotein (P-gp) for tacrolimus, which is the substrate of P-gp, the excipients which show the inhibition effect to P-gp, such as tocopheryl polyethylene glycol succinate (TPGS) and Cremophor EL40, were chosen in the SMEDDS formulations. Tacrolimus 60-70 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 98-102 21615281-3 2011 In order to inhibit the efflux of P-glycoprotein (P-gp) for tacrolimus, which is the substrate of P-gp, the excipients which show the inhibition effect to P-gp, such as tocopheryl polyethylene glycol succinate (TPGS) and Cremophor EL40, were chosen in the SMEDDS formulations. Tacrolimus 60-70 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 98-102 18822327-0 2009 Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug. Tacrolimus 94-104 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 108-112 18822327-1 2009 This study proposes a new concept of double coated nanocapsules to improve the oral bioavailability of a P-glycoprotein (P-gp) substrate drug, tacrolimus, without modulating the physiological activity of the P-gp pump. Tacrolimus 143-153 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 105-119 18822327-1 2009 This study proposes a new concept of double coated nanocapsules to improve the oral bioavailability of a P-glycoprotein (P-gp) substrate drug, tacrolimus, without modulating the physiological activity of the P-gp pump. Tacrolimus 143-153 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 121-125 16507509-0 2006 Role of P-glycoprotein in the hepatic metabolism of tacrolimus. Tacrolimus 52-62 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 8-22 16507509-1 2006 The main objective was to determine the potential effect of P-glycoprotein (P-gp) modulation on hepatic metabolism of tacrolimus, a P-gp and cytochrome P450(CYP)3A4 substrate, and to investigate various potential factors that may contribute to the interaction between P-gp and CYP. Tacrolimus 118-128 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 60-74 16507509-1 2006 The main objective was to determine the potential effect of P-glycoprotein (P-gp) modulation on hepatic metabolism of tacrolimus, a P-gp and cytochrome P450(CYP)3A4 substrate, and to investigate various potential factors that may contribute to the interaction between P-gp and CYP. Tacrolimus 118-128 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 76-80 15910387-1 2005 We encountered two cases of pediatric living-related liver transplant recipients who showed increases in blood concentration of cyclosporine or tacrolimus, a dual substrate for cytochrome P450 (CYP) 3A and P-glycoprotein (P-gp), during a diarrheal episode. Tacrolimus 144-154 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 206-220 15910387-1 2005 We encountered two cases of pediatric living-related liver transplant recipients who showed increases in blood concentration of cyclosporine or tacrolimus, a dual substrate for cytochrome P450 (CYP) 3A and P-glycoprotein (P-gp), during a diarrheal episode. Tacrolimus 144-154 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 222-226 15910387-8 2005 These findings suggest that the suppression of CYP3A and P-gp activities may be involved in the mechanism of elevated blood concentrations of cyclosporine and tacrolimus during enteritis-induced diarrhea. Tacrolimus 159-169 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 57-61 15670575-8 2005 However, the P-glycoprotein level returned to normal at 48 h. The intra-individual variation in the absorptive rate of tacrolimus was suggested to be regulated by the morphological status of the intestinal epithelium and enterocyte expression level of P-glycoprotein. Tacrolimus 119-129 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 13-27 15670575-8 2005 However, the P-glycoprotein level returned to normal at 48 h. The intra-individual variation in the absorptive rate of tacrolimus was suggested to be regulated by the morphological status of the intestinal epithelium and enterocyte expression level of P-glycoprotein. Tacrolimus 119-129 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 252-266 15670575-9 2005 Therefore, the monitoring of the enterocyte P-glycoprotein level would provide useful information for determining the dosage of tacrolimus immediately after small bowl transplantation. Tacrolimus 128-138 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 44-58 14570757-2 2003 Livers from groups of rats were perfused in a recirculatory manner following a bolus dose of tacrolimus (100 microg), a substrate for P-glycoprotein (P-gp) and CYP3A, or with felodipine (200 microg), a substrate only for CYP3A. Tacrolimus 93-103 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 134-148 15499186-4 2004 Since it has been reported that tacrolimus absorption is regulated mainly by Cytochrome P-450 (CYP) mediated metabolism in the jejunum, but by P-glycoprotein (P-gp) mediated efflux in the ileum, these factors might contribute to the changes in intestinal absorption of tacrolimus in rat of acute renal failure. Tacrolimus 32-42 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 143-157 15499186-4 2004 Since it has been reported that tacrolimus absorption is regulated mainly by Cytochrome P-450 (CYP) mediated metabolism in the jejunum, but by P-glycoprotein (P-gp) mediated efflux in the ileum, these factors might contribute to the changes in intestinal absorption of tacrolimus in rat of acute renal failure. Tacrolimus 32-42 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 159-163 15499186-4 2004 Since it has been reported that tacrolimus absorption is regulated mainly by Cytochrome P-450 (CYP) mediated metabolism in the jejunum, but by P-glycoprotein (P-gp) mediated efflux in the ileum, these factors might contribute to the changes in intestinal absorption of tacrolimus in rat of acute renal failure. Tacrolimus 269-279 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 159-163 14570757-2 2003 Livers from groups of rats were perfused in a recirculatory manner following a bolus dose of tacrolimus (100 microg), a substrate for P-glycoprotein (P-gp) and CYP3A, or with felodipine (200 microg), a substrate only for CYP3A. Tacrolimus 93-103 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 150-154 14570757-14 2003 It is concluded that GG918 increased the hepatic exposure of tacrolimus by inhibiting the canalicular P-gp transport, whereas GG918 has no effect on hepatic disposition of felodipine. Tacrolimus 61-71 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 102-106 12676880-10 2003 From these findings, it is concluded that the site-dependent differences in P-gp and/or P450 activity could be the prime cause of large intra- and interindividual variability in the oral absorption of tacrolimus. Tacrolimus 201-211 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 76-80 24934555-11 2014 The blood concentration of tacrolimus, a P-gp substrate, was lower during 0-20 min but was higher during 40-90 min post-administration compared with that in the sham-operated rats. Tacrolimus 27-37 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 41-45 32078103-1 2020 BACKGROUND AND OBJECTIVES: P-glycoprotein (P-gp) has been shown previously to contribute to the intestinal absorption of verapamil, diltiazem, tacrolimus, colchicine and indinavir in situ; however, its contribution in vivo is unknown. Tacrolimus 143-153 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 27-41 32078103-1 2020 BACKGROUND AND OBJECTIVES: P-glycoprotein (P-gp) has been shown previously to contribute to the intestinal absorption of verapamil, diltiazem, tacrolimus, colchicine and indinavir in situ; however, its contribution in vivo is unknown. Tacrolimus 143-153 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 43-47 27627555-0 2016 The Effect of P-Glycoprotein Inhibition and Activation on the Absorption and Serum Levels of Cyclosporine and Tacrolimus in Rats. Tacrolimus 110-120 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 14-28 27627555-1 2016 BACKGROUND: Permeability glycoprotein (P-glycoprotein or P-gp) plays an important role in the intestinal absorption of the immunosuppressive agents: cyclosporine and tacrolimus. Tacrolimus 166-176 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 39-53 25714622-6 2015 The mPEG113-PCC32-VE4 micelles significantly increased the absorption of P-gp substrate tacrolimus in the whole intestine. Tacrolimus 88-98 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 73-77 11920757-0 2002 Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. Tacrolimus 0-10 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 78-92 11920757-0 2002 Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. Tacrolimus 128-138 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 78-92 11920757-1 2002 The objective of this study is to investigate the role of P-glycoprotein (P-gp), a membrane efflux pump associated with multidrug resistance (MDR) and a known substrate for tacrolimus, in determining the regional intestinal permeability of tacrolimus in rats. Tacrolimus 173-183 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 58-72 11920757-1 2002 The objective of this study is to investigate the role of P-glycoprotein (P-gp), a membrane efflux pump associated with multidrug resistance (MDR) and a known substrate for tacrolimus, in determining the regional intestinal permeability of tacrolimus in rats. Tacrolimus 173-183 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 74-78 11920757-1 2002 The objective of this study is to investigate the role of P-glycoprotein (P-gp), a membrane efflux pump associated with multidrug resistance (MDR) and a known substrate for tacrolimus, in determining the regional intestinal permeability of tacrolimus in rats. Tacrolimus 240-250 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 58-72 11920757-1 2002 The objective of this study is to investigate the role of P-glycoprotein (P-gp), a membrane efflux pump associated with multidrug resistance (MDR) and a known substrate for tacrolimus, in determining the regional intestinal permeability of tacrolimus in rats. Tacrolimus 240-250 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 74-78 11920757-5 2002 The results suggest that systemic absorption of tacrolimus from the gastrointestinal tract could be significantly affected by P-gp efflux mechanisms. Tacrolimus 48-58 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 126-130 11920757-6 2002 It is also possible that differences in P-gp function at various intestinal sites in a subject or at a given intestinal site in various subjects could lead to large intra- and interindividual variability in bioavailability of tacrolimus following oral administration. Tacrolimus 226-236 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 40-44 9403721-1 1997 P-glycoprotein (P-gp) expels hydrophobic substances from the cell, including chemotherapeutic agents and immunosuppressants such as cyclosporin A (CsA) and FK506. Tacrolimus 156-161 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-14 9403721-1 1997 P-glycoprotein (P-gp) expels hydrophobic substances from the cell, including chemotherapeutic agents and immunosuppressants such as cyclosporin A (CsA) and FK506. Tacrolimus 156-161 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 16-20 26024817-1 2015 In order to improve oral bioavailability of tacrolimus (FK506), a novel poly(methyl vinyl ether-co-maleic anhydride)-graft-hydroxypropyl-beta-cyclodextrin amphiphilic copolymer (CD-PVM/MA) is developed, combining the bioadhesiveness of PVM/MA, P-glycoprotein (P-gp), and cytochrome P450-inhibitory effect of CD into one. Tacrolimus 44-54 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 244-258 26024817-1 2015 In order to improve oral bioavailability of tacrolimus (FK506), a novel poly(methyl vinyl ether-co-maleic anhydride)-graft-hydroxypropyl-beta-cyclodextrin amphiphilic copolymer (CD-PVM/MA) is developed, combining the bioadhesiveness of PVM/MA, P-glycoprotein (P-gp), and cytochrome P450-inhibitory effect of CD into one. Tacrolimus 44-54 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 260-264 26024817-1 2015 In order to improve oral bioavailability of tacrolimus (FK506), a novel poly(methyl vinyl ether-co-maleic anhydride)-graft-hydroxypropyl-beta-cyclodextrin amphiphilic copolymer (CD-PVM/MA) is developed, combining the bioadhesiveness of PVM/MA, P-glycoprotein (P-gp), and cytochrome P450-inhibitory effect of CD into one. Tacrolimus 56-61 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 244-258 26024817-1 2015 In order to improve oral bioavailability of tacrolimus (FK506), a novel poly(methyl vinyl ether-co-maleic anhydride)-graft-hydroxypropyl-beta-cyclodextrin amphiphilic copolymer (CD-PVM/MA) is developed, combining the bioadhesiveness of PVM/MA, P-glycoprotein (P-gp), and cytochrome P450-inhibitory effect of CD into one. Tacrolimus 56-61 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 260-264 26024817-6 2015 The permeability of FK506 was improved dramatically by CD-PVM/MA-NPs compared to its solution, probably due to the synergistic inhibition effect of P-gp and cytochrome P450 3A (CYP3A). Tacrolimus 20-25 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 148-152 26024817-11 2015 The present study suggested that the novel multifunctional CD-PVM/MA is a promising efficient oral delivery carrier for FK506, due to its ability in solubilization, inhibitory effects on both P-gp and CYP 3A, high bioadhesion, and sustained release capability. Tacrolimus 120-125 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 192-196 24934555-12 2014 P-gp expression in the ileum was decreased at 6 h after I/R-15, due to abnormal localization of P-gp, resulting in a high blood tacrolimus concentration in rats reperfused for 6 h. CONCLUSIONS: ROS multimodally regulate P-gp expression depending on its amount. Tacrolimus 128-138 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-4 24934555-12 2014 P-gp expression in the ileum was decreased at 6 h after I/R-15, due to abnormal localization of P-gp, resulting in a high blood tacrolimus concentration in rats reperfused for 6 h. CONCLUSIONS: ROS multimodally regulate P-gp expression depending on its amount. Tacrolimus 128-138 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 96-100 24934555-12 2014 P-gp expression in the ileum was decreased at 6 h after I/R-15, due to abnormal localization of P-gp, resulting in a high blood tacrolimus concentration in rats reperfused for 6 h. CONCLUSIONS: ROS multimodally regulate P-gp expression depending on its amount. Tacrolimus 128-138 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 96-100 23312000-2 2013 The immunosuppressant tacrolimus (TAC) is a substrate of cytochrome P450 3A2 (CYP3A2) and P-glycoprotein (P-gp) in rats. Tacrolimus 22-32 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 90-104 23312000-2 2013 The immunosuppressant tacrolimus (TAC) is a substrate of cytochrome P450 3A2 (CYP3A2) and P-glycoprotein (P-gp) in rats. Tacrolimus 22-32 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 106-110